September 1, 2015Open Access

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

Key Points

Key points are not available for this paper at this time.

Abstract

Adjuvant erlotinib did not prolong DFS in patients with EGFR-expressing NSCLC or in the EGFRm-positive subgroup. Further evaluation of erlotinib is warranted in the EGFRm-positive subgroup.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Karen Kelly

Nasser K. Altorki

Wilfried Eberhardt

Journals

Journal of Clinical Oncology

Actions

Institutions

Cornell University

Presbyterian Hospital

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study